GYS1 and Glycogen storage disease due to acid maltase deficiency: It is expected that GYS1 ASOs have the potential to be used as an alternative treatment approach, as monotherapy in LOPD with little or no cardiac involvement, or in combination with ERT primarily for IOPD in future clinical trials for patients with Pompe disease.